Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(50.0%)
N/A
1(50.0%)
2Total
Phase 3(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06933615Not ApplicableActive Not Recruiting

Mobile Individual Atrial Fibrillation Management Program

Role: collaborator

NCT04411433Phase 3Unknown

Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19

Role: collaborator

NCT04474457Unknown

Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age

Role: collaborator

All 3 trials loaded